The FDA is deciding on recommending MDMA with talk therapy for PTSD treatment, a critical step toward approval.
FDA staff identified uncertainties in clinical research, including questions about abuse potential and the therapeutic approach's effectiveness.
Allegations of misconduct and bias in MDMA trials have been raised, prompting FDA investigation.
If approved, MDMA would be the first new PTSD treatment in decades, marking a shift and potential milestone in psychedelics access.
[
add
]
[
|
|
...
]